RE:RE:RE:RE:RE:RE:RE:RE:RE:Told you, what did you expectIt was an email. I don't call in. I don't need platitudes or more of what you get on their live streamed interviews.
I wanted to know if NXO did their due diligence on Pristine Surgical, or are they only seeing the tree instead of the forest.
1. The NR indicates a number - 25 million procedures. I asked, of these 25 million, what is the market share for PS? What % of the market do they control?
2. If what is being communicated is incorrect, on their website, they indicate they have No product approved for sale. If that is the case, what is their target for approval? Do they have a manufacturer set up? What is their timeline for having a viable product to market?
3. Of that possible potential, what is the % ALIIS would bring to NXO? What are the numbers.
I said the NR was midleading, and I wasn't impressed by the Webinar.
Bill didn't answer any questions and only focused on my opinion of the NR and Webinar.
Well, that doesn't answer things - also demonstrates that perhaps either he doesn't know, or NXO didn't bother to find out these answers from Pristine Surgical.
If PS isn't to market yet and only have an initial 501K FDA approval, they could be a year or more away from product to market - and then past that time for NXO to gain any funding from those prospects.
As an investor who lost significant funds on this last NR, I think I was within my rights to ask those tough questions - which were side stepped and avoided. Therefore, their silence answered my questions. They didn't bother doing their DD on PS.